Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
暂无分享,去创建一个
A Sulli | M Cutolo | M. Cutolo | A. Sulli | C. Pizzorni | C Pizzorni | C Craviotto | B Seriolo | B. Seriolo | M Tuccio | A Burroni | M Basso | C. Craviotto | M. Tuccio | A. Burroni | M. Basso | M. Cutolo | A. Sulli
[1] T Moore,et al. Quantitation of microcirculatory abnormalities in patients with primary Raynaud's phenomenon and systemic sclerosis by video capillaroscopy. , 2000, Rheumatology.
[2] R. Fleischmajer,et al. Immunopathogenesis of scleroderma--evolving concepts. , 2001, The Mount Sinai journal of medicine, New York.
[3] A. Silman,et al. A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.
[4] C. Black. Systemic sclerosis 'state of the art' 1995. , 1995, Scandinavian journal of rheumatology.
[5] R. Scorza,et al. Lymphocyte-endothelium interaction in systemic sclerosis and Raynaud's phenomenon. , 2001, Clinical and experimental rheumatology.
[6] T. Medsger,et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.
[7] H. Maricq,et al. A prospective study of Raynaud phenomenon and early connective tissue disease. A five-year report. , 1982, The American journal of medicine.
[8] M. Jayson,et al. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. , 1993, The Journal of rheumatology.
[9] E. Atra,et al. Panoramic nailfold capillaroscopy: a new reading method and normal range. , 1990, Seminars in arthritis and rheumatism.
[10] E Michoud,et al. Digitized nailfold capillaroscopy. , 1994, VASA. Zeitschrift fur Gefasskrankheiten.
[11] A. Silman,et al. European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes , 2001, Annals of the rheumatic diseases.
[12] M. Cutolo,et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. , 2001, Rheumatology.
[13] J. Pearson,et al. The endothelium: its role in scleroderma. , 1991, Annals of the rheumatic diseases.
[14] Maricq Hr,et al. Microvasculature in systemic sclerosis. , 1990 .
[15] Richard W. Martin,et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. , 2002, Arthritis and rheumatism.
[16] Maurizio Cutolo,et al. Raynaud's phenomenon and the role of capillaroscopy. , 2003, Arthritis and rheumatism.
[17] M. Hasegawa,et al. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. , 2001, Rheumatology.
[18] P. Priollet,et al. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases. , 1987, The American journal of medicine.
[19] N Houtman,et al. Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. , 2000, The Journal of rheumatology.
[20] E. Tan,et al. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. , 1983, Clinical and experimental rheumatology.
[21] R. Abbate,et al. High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. , 2002, The American journal of medicine.
[22] M. Conforti,et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers , 2002, Arthritis research.
[23] M. Ahern,et al. A study of scleroderma in South Australia: prevalence, subset characteristics and nailfold capillaroscopy. , 1995, Australian and New Zealand journal of medicine.
[24] H. Anders,et al. Differentiation between primary and secondary Raynaud's phenomenon: a prospective study comparing nailfold capillaroscopy using an ophthalmoscope or stereomicroscope , 2001, Annals of the rheumatic diseases.
[25] T. Medsger,et al. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.
[26] M. Lovy,et al. Relationship between nailfold capillary abnormalities and organ involvement in systemic sclerosis. , 1985, Arthritis and rheumatism.
[27] T. Medsger,et al. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease. , 1985, Arthritis and rheumatism.
[28] D. Blockmans,et al. Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases , 1996, Clinical Rheumatology.
[29] M. Kuwana,et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. , 1994, Arthritis and rheumatism.
[30] P. von Wichert,et al. Intravital microscopy and capillaroscopically guided nail fold biopsy in scleroderma. , 1996, Annals of the rheumatic diseases.
[31] A. Masi. Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.
[32] A. Gelber,et al. Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. , 2002, Arthritis and rheumatism.
[33] H. Maricq,et al. Widefield capillary microscopy. technique and rating scale for abnormalities seen in scleroderma and related disorders , 1981 .
[34] E Mannarino,et al. Nailfold Capillaroscopy in the Screening and Diagnosis of Raynaud's Phenomenon , 1994, Angiology.
[35] D. Abraham,et al. Transforming growth factor-&bgr; and connective tissue growth factor: key cytokines in scleroderma pathogenesis , 2001, Current opinion in rheumatology.
[36] W. Earnshaw,et al. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. , 1988, Arthritis and rheumatism.
[37] M. Alavi,et al. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis , 2002, Annals of the rheumatic diseases.
[38] J. Raynauld,et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. , 2001, Arthritis and rheumatism.
[39] J. F. Wolfe,et al. Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. , 1980, Arthritis and rheumatism.
[40] E F Ring,et al. Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. , 1996, Annals of the rheumatic diseases.
[41] Y. Okano,et al. Antinuclear antibody in systemic sclerosis (scleroderma). , 1996, Rheumatic diseases clinics of North America.
[42] Jane Worthington,et al. Genetic epidemiology: Systemic sclerosis , 2002, Arthritis Research & Therapy.
[43] S. Rantapää-Dahlqvist,et al. Assessment of vascular function in systemic sclerosis: indications of the development of nitrate tolerance as a result of enhanced endothelial nitric oxide production. , 2002, Arthritis and rheumatism.
[44] E. Leroy,et al. Raynaud's phenomenon and scleroderma. , 1981, Comprehensive therapy.
[45] T. Medsger,et al. Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.
[46] E. Sato,et al. Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients , 2002, Lupus.
[47] A. Sulli,et al. Lack of correlation between gastric Helicobacter pylori infection and primary or secondary Raynaud's phenomenon in patients with systemic sclerosis. , 2000, The Journal of rheumatology.
[48] M. Cerinic,et al. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. , 1995, Arthritis and rheumatism.
[49] C. Black,et al. The aetiopathogenesis of systemic sclerosis , 1993, Journal of internal medicine.
[50] Y. Shoenfeld,et al. Anti-Endothelial Cell Antibodies (AECA) in Systemic Sclerosis - Increased Sensitivity using Different Endothelial Cell Substrates and Association with Other Autoantibodies , 2001, Autoimmunity.
[51] R M Silver,et al. Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. , 1984, The American journal of medicine.
[52] E. Hess,et al. Prospective study of the evolution of Raynaud's phenomenon. , 1988, The American journal of medicine.
[53] P. Vitali,et al. Evidence of cerebral hypoperfusion in scleroderma patients. , 2000, Rheumatology.